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Abstract 
Background: Performing selective coronary angiogram (CA) and percutaneous coronary 
intervention (PCI) post transcatheter aortic valve implantation (TAVI) may be challenging 
with various success rates of coronary ostia engagement.  
Methods: Among all patients who underwent CA and/or PCI after TAVI from the 
documented single center TAVI registry, ostia cannulation success was reported according to 
the quality of ostia engagement and artery opacification, and was classified as either selective, 
partially selective or non-selective but sufficient for diagnosis. 
Results: Among the 424 consecutive TAVI procedures performed at the aforementioned 
institution, 20 (4.7%) CA were performed in 19 (4.5%) patients at a median time of 464 days 
post TAVI (25–75% IQ: 213–634 days). CA were performed in 7 CoreValve, 9 Evolut R, 1 
Evolut PRO and 2 Edwards Sapien 3 devices. Transradial vascular approach was attempted in 
9 procedures (45%, right n = 6 and left n = 3) and was successful in 8 (40%) patients. A total 
of 20 left main artery ostium cannulation were attempted leading to a diagnostic CA in all of 
them with selective engagement in 65%.  Engagement of the right coronary artery in 2 out of 
15 attempted cases failed due to a low ostium in conjunction with a high implantation of a 
CoreValve prosthesis. 11 PCI (55% of CA) including 2 left main lesions were performed. In 4 
patients (36.4% of the PCI), an extension catheter was required to engage the left main. All 
planned PCI were successful.  
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Conclusions: Post TAVI CA and PCI are challenging but feasible even after supra-annular 
self-expandable valve implantation. 
Key words: transcatheter aortic valve implantation, coronary angiogram, percutaneous 
coronary intervention, self-expandable transcatheter heart valve 
  
Introduction 
Aortic stenosis (AS) and coronary artery disease share common risk factors and not 
surprisingly are often associated and the prevalence of both increases with an aging 
population [1, 2]. In the United Kingdom transcatheter aortic valve implantation (TAVI) 
registry, one, two and three vessel disease were found in 21.1%, 11.5% and 13.2%, 
respectively and thus almost half (45.7%) of the patients had a concomitant coronary artery 
disease (CAD) [3].  
Management of stable CAD in patients with AS planned for TAVI remains 
controversial. To date, there is no evidence showing the prognostic significance of performing 
coronary artery revascularization before, at the time or after the TAVI procedure [4, 5]. 
Despite this controversial topic, the recent myocardial revascularization guidelines of the 
European Society of Cardiology suggest that patients undergoing TAVI with coronary artery 
stenosis > 70% in proximal segments should be considered for prior percutaneous coronary 
intervention (PCI) [6]. Similarly, the latest appropriate use criteria of the American Society of 
Cardiology suggests coronary artery revascularization before TAVI [7]. More information 
will be obtained from the first randomized control trial ACTIVATION (Percutaneous 
Coronary Intervention Prior to Transcatheter Aortic Valve Implantation; ISRCTN75836930) 
currently recruiting patients and comparing PCI of significant coronary artery stenosis before 
TAVI versus medical management [8]. Nevertheless, the recent extension of TAVI to lower 
risk and younger patients will undoubtedly increase the need for future coronary angiogram 
(CA) and PCI post TAVI.  
Performing selective CA and PCI post TAVI may represent a technical challenge with 
various success rates of coronary ostia engagement depending on the transcatheter heart valve 
type, supra-annular valves with long stent frames being potentially the most challenging. 
Additional factors such as the height of implantation and the orientation of the commissures 
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may increase the challenge.  Hereby reported are the technical characteristics and challenges 
faced when performing CA and PCI in patients post TAVI from this single center experience.  
 
Methods 
  Data was extracted from all patients who underwent CA and/or PCI after TAVI from 
the present single center registry of transcatheter heart valves. Demographic data and TAVI 
procedure characteristics of the identified patients were taken from the local prospective 
TAVI registry. All patients gave written informed consent for the use of their anonymous 
related data for research.  
All procedures studied were retrospectively reviewed by an interventional cardiologist 
(SN). For each CA, vascular access, contrast volume, fluoroscopy time and catheter type used 
were reported. Subjective complexity and the success of coronary artery cannulation were 
evaluated. Ostia cannulation success was reported according to the quality of ostia 
engagement and artery opacification, and classified as either selective, partially selective or 
non-selective but sufficient for diagnosis when the distal part of the arteries as well as all their 
branches were visualized (Fig. 1). 
Before TAVI, all patients underwent multi-slice computed tomography to evaluate 
aortic annulus and root dimensions and calcifications. CA was routinely performed and 
patients with significant coronary artery lesions underwent PCI before or at the time of valve 
replacement at the operators’ discretion. Significant lesions were defined according to the 
European guidelines on myocardial revascularization [6]. TAVI was performed mainly 
through the transfemoral approach as previously described [9]. Among patients analyzed in 
this report, implanted prosthesis were mainly Medtronic self-expandable devices (CoreValve 
n = 7, Evolut R n = 9 and Evolut PRO n = 1) with 2 Edwards Sapien 3 devices (Table 1). 
After TAVI, patients were prescribed a double antiplatelet therapy including clopidogrel for 3 
months and acetylsalicylic acid (ASA) life-long. In patients with an indication for long-term 
oral anticoagulation, ASA was added for 1 month followed by anticoagulation alone unless 
they had undergone recent PCI (< 6 months).  
Continuous variables are expressed as mean ± standard deviation and categorical 
variables are shown as proportions (%).  
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Results 
Among 424 consecutive TAVI procedures (CoreValve 39.1%, Evolut R and Pro 
55.0%, Edwards SAPIEN 5.4%, Acurate neo 0.5%) performed at the present institution 
between August 2008 and April 2019, respectively 32.0% and 7.8% had prior PCI or 
coronary artery bypass grafting (CABG). During the TAVI procedure concomitant PCI was 
performed in 9.0% of the cases. During follow-up, 20 (4.7%) CA were performed in 19 
(4.5%) patients post TAVI. Mean age of the latter patients was 77.7 ± 7.2 years, with a mean 
Society of Thoracic Surgeons score of 5.5 ± 3.4%. Ten patients (52.6% of CA) had prior PCI 
and 5 (26.3%) patients had previously been treated by CABG prior to the TAVI procedure. 
Table 1 presents patient baseline demographic characteristics.   
CA was performed at a median time of 464 days post TAVI (25–75% IQ: 213–634 
days) and at a mean time of 554 ± 435 days. Eight (40.0%) CA were performed for acute 
coronary syndrome including two ST-segment elevation myocardial infarction (10.0%), both 
involving the left circumflex artery. 
Procedural characteristics of CA are detailed in Table 2. Transradial vascular approach 
was attempted in 9 procedures (45.0%, right n = 6 and left n = 3) with acceptable images in 8 
(40.0%) patients including 6 selective or partially selective ostia cannulation. One cross-over 
(5.0%) from a right transradial to a transfemoral access was needed. 
A total of 20 left main artery (LM) ostium cannulation were attempted leading to a 
diagnostic CA in all of them (100%). Thirteen of these (65.0%, CoreValve n = 6/7, Evolut R 
n = 6/9, Edwards n = 1/2) were selectively engaged (Table 2). In 12/20 CA (60.0%), the use 
of one diagnostic catheter was sufficient to successfully cannulate the LM ostia using mostly 
5 or 6 French Judkins Left (JL) 3.5 to 4.5 catheters. For the 8 remaining procedures, ostia 
engagement needed additional catheters including Multipurpose and/or Amplatz Left (AL) 
catheters. For the same patients, pre-TAVI CA were performed using standard catheters (JL 
or Judkins Right [JR]). 
Right coronary artery (RCA) cannulation was attempted in only 15 cases (75.0% of 
CA) because of known RCA total chronic occlusion, minor vessels with left dominance or 
low renal clearance in the absence of RCA territory ischemia based on electrocardiogram, 
echocardiogram or myocardial scintigraphy. It was possible to engage selectively and non-
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selectively respectively in 10 (66.7%) and 3 (20.0%) RCA using the JR catheter in 8/15 RCA 
CA and an additional catheter (including AL, Tiger, Multipurpose, 3DRC and right coronary 
bypass catheter) in the remaining patients.  Failure to engage the RCA in 2 cases occurred due 
to a low ostium in conjunction with a high implantation of a CoreValve prosthesis 
(implantation depth at 0mm in both cases).  
11 coronary artery lesions (55.0% of CA) were treated including 2 LM lesions (Table 
2). One of the LM PCI (Edwards case) was performed with extracorporeal membrane 
oxygenation (ECMO) support due to a very calcified distal LM subocclusion requiring 
rotablation, a significant proximal left anterior descending and circumflex artery stenosis and 
2 occluded saphenous vein grafts. Withdrawing the ECMO was accomplished at the end of 
the procedure without any complications. In 4 patients (36.4% of the PCI), an extension 
catheter (GuideLiner, Vascular Solutions Inc.) was needed to help the appropriate guiding 
catheter engagement in the LM. The exchange from the diagnostic catheter to the guiding 
catheter was performed over an extended 0.014 wire (extension wire Asahi, Tokyo, Japan) 
and a second guidewire, either a 0.35 or 0.18 wire. All planned PCI were successful. No case 
of hemodynamically significant acute prosthesis dysfunction was reported after CA or PCI.  
 
Discussion 
This descriptive study aimed to look at the technical characteristics and challenges of 
performing CA and PCI post TAVI from a single center experience. The main findings and 
learning points derived from this study are as follows:  
— The need for CA and PCI after TAVI is low (4.7% and 2.6%, respectively); 
— Post TAVI CA and PCI remain challenging, but are feasible even after supra-annular 
self-expandable valve prosthesis implantation; 
— With self-expanding devices with a long stent frame and reduced possibilities of 
standard catheter manipulation, favoring the left radial or transfemoral approaches 
over the right radial approach is herein suggested; 
— Catheter extension facilitates appropriate guiding catheter engagement in the coronary 
ostia and were used in 36.4% of the cases.  
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At the documented institution, all patients underwent pre-TAVI coronary artery 
assessment with revascularization of clinically indicated lesions at the operators’ discretion. 
This led to a low incidence of CA following TAVI (4.7%) but similar to a rate  published the 
series [10–12].  CA was performed at a median time of 464 days post TAVI (25–75% IQ: 
213–634 days). 
When considering coronary access, post TAVI, different challenges have been reported, 
particularly with self-expandable prostheses [13]. Indeed, among the largest observational 
studies published by Zivelonghi et al. [11], only standard catheters were used to cannulate 
coronary ostia of 41 patients after Sapien 3 (Edwards Lifesciences, Irvine, California) 
prosthesis implantation. Challenges may be encountered in the case of large Sapien 
prostheses, highly implanted with borderline coronary ostium height. In this setting, the stent 
frame of the Edwards valve will most commonly cover the coronary ostia. Therefore, in order 
to cannulate the ostia, the catheter will have to cross the stent frame, similarly as with a supra-
annular prosthesis with a long stent frame. This raises several technical challenges due to 
anatomical, device-related and procedural considerations.  
The space to manipulate the catheter is reduced in the presence of a long stent frame, even 
more so with a waisted frame such as the CoreValve. Of note, the stent frame shape of the 
Evolut R and Pro have had some iteration with respect to the waist shape and cell size. Since 
with right radial access, shorter catheters are commonly used than with left radial or 
transfemoral approaches, in the context of a CoreValve frame which reduces the width of the 
aortic root, it is highly challenging to manipulate the classical catheters. Therefore, it was 
believed that the left radial or transfemoral approaches should be favored. In a different series 
reported (Table 3) [10, 11, 14–19], most operators also preferred alternative access to the 
right radial access. In a series from an expert radial center, transradial rate (without data for 
left or right) was only 70% compared to more than 90% in their global activity [20]. In 
agreement with Yudi et al. [13], who recommends the use of 5 F or 6 F guiding catheters and 
avoiding 7 F or 8 F guiding catheters since they are too bulky within the limited space offered 
by the stent frame.  
Valve implantation depth also plays a major role in supra-annular or long stent frame 
prostheses. High valve implantation (particularly with low coronary ostium position) might 
place the sealing skirt at the level of the coronary ostium and prevent coaxial cannulation 
[20]. In this situation, the catheter has to pass through the stent struts above the coronary 
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ostia. From previous experience, among 3 highly implanted prosthesis, borderline-selective 
and non-selective left side CA, with standard JL catheters among 2 of them were performed. 
In a third patient the use of additional catheters was needed, finally succeeding with an EBU 
catheter. On the other hand, right CA with highly implanted prosthesis was unsuccessful in 2 
of these patients and was not performed in the remaining patient due to known chronic total 
occlusion.  
Importantly, coronary ostia should, , be engaged through a diamond at the level of the 
ostium as much as possible, since catheter kinking and entrapment has been described when 
engaging from a diamond below the ostium with catastrophic outcomes [21].  
Overall, diagnostic left and right CA were performed in 100% and 90% respectively of 
patients at the expense of additional manipulations using up to 5 different catheters and 
prolonged fluoroscopic time (13.6 ± 7.9 min for diagnostic CA alone).   
About half of patients of the cohort (48%) underwent PCI. Whereas unselective coronary 
injection might be sufficient for diagnostic purposes, coaxial catheter engagement is 
important to increase support and perform a safe PCI. In case of ostium cannulation 
difficulties, a coronary wire can be placed in the left main or RCA with or without inflating a 
balloon (anchoring balloon technique) and be used as a rail guiding the catheter. If 
unsuccessful, an extension catheter can afford selective coronary ostium cannulation. With 
these techniques, the present study was able to successfully perform all planned PCI using an 
extension catheter in 36% of patients. Of note, in 3 cases where it was difficult to engage the 
ostium with the diagnostic catheter, an 0.014 extra-support blue Sion wire with an extension 
wire (Asahi) was introduced into the coronary artery and in parallel, an additional 260 cm 
0.18” or 0.35” stiff wire in the aortic root in order to exchange the diagnostic catheter for the 
guiding catheter. To overcome the technical difficulty to cannulate the coronary ostia, 
designing dedicated coronary guiding catheters (i.e. orientable, different shapes) might be of 
interest for post TAVI PCI. 
Finally, transcatheter heart valves are deployed in the aortic root without consistent 
prosthetic and native leaflet superposition. The resultant commissural mis-alignment could 
lead to coronary ostium overlap compromising future coronary access [22, 23]. In a pilot 
study, Tang et al. [24] evaluated commissural orientation and coronary overlap according to 
their initial deployment orientation, by computed tomography imaging. After the implantation 
of a Medtronic Evolut valve, ostium overlap occurred more frequently when the capsule hat 
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orientation faced the inner curve of the aorta or was in the center but posteriorly located in a 
standard left oblique view. 
Durability of transcatheter aortic heart valves have recently shown favorable results at 5 
years, but limited data above 7 years [25] remains. However, when treating younger patients 
with longer life expectancy, valve degeneration might occur and can be managed in selected 
patients by implanting a second transcatheter heart valve in the degenerated prosthesis (TAV-
in-TAV) [26]. The degenerated prosthetic leaflets will thus be pushed against the stent frame 
at the expense of increased difficulty to pass through the struts. Here again, a short stent frame 
prosthesis implanted in a previous intra-annular or supra-annular prosthesis will only rarely 
compromise coronary access contrary to supra-annular prosthesis implanted in a degenerated 
long or short stent frame prosthesis. In the worst case of TAV-in-TAV using 2 long stent 
frame prosthesis, overlap of the 2 misaligned commissures can lead to a hermetic tissue 
obstruction up to the sinotubular junction and definitively prevent coronary access [27].  
 
Limitation of the study 
The main limitation of this study is its retrospective design and the inclusion of a small 
number of patients due to the low incidence of CA post TAVI. Procedural or technical 
predictors of CA success were thus not calculated because of the small statistical power 
precluding any relevant results. CA were performed by experienced operators in coronary 
interventions but vary in experience in the TAVI field. Even though this might cause an 
overestimation in subjective difficulty in coronary ostia engagement, it reflects real life in the 
catheterization laboratory. 
 
Conclusions 
Post TAVI coronary angiogram and PCI are challenging but feasible even after supra-
annular self-expandable valve implantation. High implantation of TAVI reduces the need for 
new pacemaker implantation, but may increase the challenge of coronary artery cannulation 
especially if coronary ostia are low. Use of a catheter extension is often needed to perform 
PCI, post TAVI. Valve design according to patient anatomical characteristics should be part 
of the prosthesis selection process at the time of TAVI procedure as it could affect future 
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coronary access. In addition, orientation of the commissure during deployment seems to be an 
important feature to develop for new devices in order to facilitate recannulation of  coronary 
arteries.  
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Table 1. Baseline characteristics. 
 Overall (n = 
19) 
 
Sex 
Female 
 
 
6 (31.6%) 
Age, years (at the time of 
TAVI) 
77.7 ± 7.2 
BMI [kg/m2] 26.7 ± 4.4 
STS score [%] 5.5 ± 3.4 
Comorbidities:  
Dyslipidemia 15 (78.9%) 
Diabetes mellitus 8 (42.1%) 
Hypertension 15 (78.9%) 
COPD 6 (31.6%) 
PVD  4 (21.1%) 
Previous MI 4 (21.1%) 
Previous CABG 5 (26.3%) 
Previous PCI 10 (52.6%) 
Previous cerebral stroke 2 (10.5%) 
12 
Ejection fraction [%] 52.1 ± 15.2 
Valve type 
CoreValve 
Evolut R 
Evolut PRO 
Edwards Sapien 
 
7 (36.8%) 
9 (47.4%) 
1 (5.3%) 
2 (10.5%) 
Valve size [mm]: 
23 
26 
29 
31 
34 
 
5 (26.3%) 
4 (21.1%) 
6 (31.6%) 
3 (15.8%) 
1 (5.3%) 
Valve position: 
Low (> 8 mm) 
Optimal (2–8 mm) 
High (< 2 mm) 
 
2 (10.5%) 
14 (73.7%) 
3 (15.8%) 
Values are number (%) or mean  standard deviation. BMI — body mass index; CABG — coronary artery 
bypass graft; COPD — chronic obstructive pulmonary disease; LVEF — left ventricular ejection fraction; MI — 
myocardial infarction; PCI — percutaneous coronary intervention; PVD — peripheral vascular disease; STS — 
Society of Thoracic Surgeons 
 
 
Table 2. Procedural characteristics. 
 Overall (CA, n = 
20) 
Indication of CA: 
STEMI 
NSTEMI 
Stable angina 
Other 
 
2 (10.0%) 
6 (30.0%) 
9 (45.0%) 
3 (15.0%) 
Days post-TAVI 554 ± 435 
Vascular access: 
Radial right 
Radial left 
Femoral 
 
5 (25.0%) 
3 (15.0%) 
12 (60.0%) 
Difficulty of coronary artery 
cannulation: 
Easy  
Intermediate 
Difficult  
 
7 (35.0%) 
7 (35.0%) 
6 (30.0%) 
Success of coronary artery selective 
injection: 
LM (n = 20): 
Selective 
Partially-selective 
Non-selective 
Failure 
RCA (n = 15):  
Selective 
Incomplete selective 
 
 
9 (45.0%) 
4 (20.0%) 
7 (35.0%) 
0 (0%) 
 
7 (35.0%) 
3 (15.0%) 
3 (15.0%) 
13 
Non-selective 
Failure 
2 (10.0%) 
Number of catheters used for 
cannulation: 
LM 
RCA 
 
2.0 ± 1.4 (min. 1, 
max. 5) 
1.2 ± 0.8 
Number of PCI performed: 
LM 
LAD 
LCx 
RCA 
11 (55.0%) 
3 (15.0%) 
3 (15.0%) 
3 (15.0%) 
2 (10.0%) 
Mean procedural time [min]: 
CA alone 
CA + PCI 
47.0 ± 31.1 
24.2 ± 18.7 
77.0 ± 21.6 
Mean fluoroscopy time [min], overall: 
CA alone 
CA + PCI 
25.2 ± 14.7 
13.6 ± 7.9 
35.5 ± 11.1 
Amount of contrast used [mL], overall: 
CA alone 
CA + PCI 
125.0 ± 55.8 
78.8 ± 29.1 
166.1 ± 38.1 
Values are number (%) or mean  standard deviation. CA — coronary angiography; LAD — Left anterior 
descending coronary artery; LCx — left circumflex coronary artery; LM — left main coronary artery; NSTEMI 
— non-ST segment elevation myocardial infarction; PCI — percutaneous coronary intervention; RCA — right 
coronary artery; STEMI — ST segment elevation myocardial infarction; TAVI — transcatheter aortic valve 
implantation
Table 3. Largest series reported in the literature summarizing technical aspects of coronary access following transcatheter aortic valve implantation.  
Study Date Number 
of valves 
Mean duration 
TAVI-CA/PCI 
Type of valve Number 
of CA 
Number of 
PCI 
PCI success 
rate 
Vascular access Number of 
catheters used 
Blumenstein et al., 
2015 [14] 
2011–2014 1000 233 ± 158 days Edwards (n = 19) 
JenaValve (n = 1) 
CoreValve (n = 10) 
Acurate (n = 4) 
Portico (n = 1) 
35 (3.5%) 8 (0.8%) 100% NA NA 
Allali et al., 2016 
[15] 
2007–2014 296 17.7 (1–72) months CoreValve NA 17 (5.7%) 95.8% (1 death 
perprocedure) 
Femoral 100% Median 1 (1–
10) 
Zivelonghi et al., 
2017 [11] 
2015–2016 66  Edwards (n = 41) 
Evolut R (n = 25) 
66 (100%) 17 (25.6%) 100% Femoral 100% NA 
Htun et al., 2017 
[10] 
2012–2016 403 15.0 months CoreValve (n = 23) 
Evolut R (n = 5) 
28 (6.9%) 29 lesions 100% Femoral: 83% 
Radial: 17% 
NA 
Boukantar et al., 
2017 [16] 
2007–2015 550 NA CoreValve 16 (2.9%) 7 (1.3%) 86% (1 poor 
backup in LAD) 
Femoral: 44% 
Left radial: 56% 
3.6 ± 1.4 
Ferreira-Neto et al., 
2019 [17] 
Ca. 2010–
2019 
616 CA:748 ± 686 days 
PCI: 603 ± 516 days 
Edwards 28 (4.6%) 13 (2.1%) 100% Femoral: 36% 
Radial: 64% 
LM: 1.04 ± 0.33 
RCA: 0.96 ± 
0.58 
Tanaka et al., 2019 
[18] 
2007–2016 2170 379 (83–1045) 
months 
CoreValve and 
Evolut R 
32 (1.5%) 30 (1.4%) 93.3% (coronary 
obstruction 
during TAVI) 
NA LM: 1.8 ± 1.5 
RCA: 1.2 ± 0.4 
Couture et al., 2020 
[20] 
2015–2019 203 12 ± 8 months Evolut R and Pro 10 (4.9%) 2 (1.0%) 50% (1 failure 
of selective 
RCA 
cannulation) 
Radial 70% LM: 1.5 ± 0.5 
RCA: 2.1 ± 0.5 
Ochiai et al., 2020 
[19] 
2015–2017 411 NA Evolut R and Pro 
and Edwards 
56 
(13.6%) 
38 (9.2%) 97.4% Femoral: 18% 
Radial: 82% 
NA 
Values are mean ± standard deviation or median (interquartile range). CA — coronary angiography; LAD — left anterior descending artery; LM — left main; NA — not 
available; PCI — percutaneous coronary intervention; RCA — right coronary artery; TAVI — transcatheter aortic valve implantation
Figure 1. Selective (A), partially selective (B) or non-selective (C) coronary ostium 
cannulation. The white arrows show position of the catheter tip. 
 

